Cargando…

Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer

The 2017 PACIFIC trial heralded the incorporation of routine adjuvant durvalumab following curative-intent chemoradiation for stage III non-small-cell lung cancer (NSCLC). However, carefully selected clinical trial populations can differ significantly from real-world populations, which can have impl...

Descripción completa

Detalles Bibliográficos
Autores principales: Preti, Beatrice T. B., Sanatani, Michael S., Breadner, Daniel, Lakkunarajah, Suganija, Scott, Carolyn, Esmonde-White, Caroline, McArthur, Eric, Rodrigues, George, Chaudhary, Mitali, Mutsaers, Adam, Sachdeva, Robin, Vincent, Mark D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453685/
https://www.ncbi.nlm.nih.gov/pubmed/37623040
http://dx.doi.org/10.3390/curroncol30080559
_version_ 1785095997647486976
author Preti, Beatrice T. B.
Sanatani, Michael S.
Breadner, Daniel
Lakkunarajah, Suganija
Scott, Carolyn
Esmonde-White, Caroline
McArthur, Eric
Rodrigues, George
Chaudhary, Mitali
Mutsaers, Adam
Sachdeva, Robin
Vincent, Mark D.
author_facet Preti, Beatrice T. B.
Sanatani, Michael S.
Breadner, Daniel
Lakkunarajah, Suganija
Scott, Carolyn
Esmonde-White, Caroline
McArthur, Eric
Rodrigues, George
Chaudhary, Mitali
Mutsaers, Adam
Sachdeva, Robin
Vincent, Mark D.
author_sort Preti, Beatrice T. B.
collection PubMed
description The 2017 PACIFIC trial heralded the incorporation of routine adjuvant durvalumab following curative-intent chemoradiation for stage III non-small-cell lung cancer (NSCLC). However, carefully selected clinical trial populations can differ significantly from real-world populations, which can have implications on treatment toxicities and outcomes, making it difficult to accurately counsel patients. Consequently, we performed a real-world, retrospective analysis of outcomes and toxicities in 118 patients with stage III NSCLC treated with durvalumab after platinum-based chemoradiotherapy. The data were collected from patients who underwent treatment at a single, tertiary-level Canadian cancer centre from May 2018 to October 2020. The variables collected included patient demographics, treatment specifics, progression-free survival, overall survival, and immune-related adverse events (IRAE) from durvalumab. Descriptive statistics were used for toxicity analysis, and progression-free survival and overall survival estimates were calculated using the Kaplan–Meier method. The statistical analyses indicated a 64.4% (n = 76) toxicity rate, with a 21% (n = 25) toxicity rate of grade 3+ IRAEs. The most common documented IRAEs were pneumonitis (n = 44; 40%), followed by rash (n = 20; 18%) and thyroid dysfunction (n = 17; 15%). FEV1 and DLCO were not found to be associated predictors of pneumonitis toxicity. The median PFS and OS were estimated to be >1.7 years and >2.7 years, respectively.
format Online
Article
Text
id pubmed-10453685
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104536852023-08-26 Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer Preti, Beatrice T. B. Sanatani, Michael S. Breadner, Daniel Lakkunarajah, Suganija Scott, Carolyn Esmonde-White, Caroline McArthur, Eric Rodrigues, George Chaudhary, Mitali Mutsaers, Adam Sachdeva, Robin Vincent, Mark D. Curr Oncol Communication The 2017 PACIFIC trial heralded the incorporation of routine adjuvant durvalumab following curative-intent chemoradiation for stage III non-small-cell lung cancer (NSCLC). However, carefully selected clinical trial populations can differ significantly from real-world populations, which can have implications on treatment toxicities and outcomes, making it difficult to accurately counsel patients. Consequently, we performed a real-world, retrospective analysis of outcomes and toxicities in 118 patients with stage III NSCLC treated with durvalumab after platinum-based chemoradiotherapy. The data were collected from patients who underwent treatment at a single, tertiary-level Canadian cancer centre from May 2018 to October 2020. The variables collected included patient demographics, treatment specifics, progression-free survival, overall survival, and immune-related adverse events (IRAE) from durvalumab. Descriptive statistics were used for toxicity analysis, and progression-free survival and overall survival estimates were calculated using the Kaplan–Meier method. The statistical analyses indicated a 64.4% (n = 76) toxicity rate, with a 21% (n = 25) toxicity rate of grade 3+ IRAEs. The most common documented IRAEs were pneumonitis (n = 44; 40%), followed by rash (n = 20; 18%) and thyroid dysfunction (n = 17; 15%). FEV1 and DLCO were not found to be associated predictors of pneumonitis toxicity. The median PFS and OS were estimated to be >1.7 years and >2.7 years, respectively. MDPI 2023-08-18 /pmc/articles/PMC10453685/ /pubmed/37623040 http://dx.doi.org/10.3390/curroncol30080559 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Preti, Beatrice T. B.
Sanatani, Michael S.
Breadner, Daniel
Lakkunarajah, Suganija
Scott, Carolyn
Esmonde-White, Caroline
McArthur, Eric
Rodrigues, George
Chaudhary, Mitali
Mutsaers, Adam
Sachdeva, Robin
Vincent, Mark D.
Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer
title Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer
title_full Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer
title_fullStr Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer
title_full_unstemmed Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer
title_short Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer
title_sort real-world analysis of durvalumab after chemoradiation in stage iii non-small-cell lung cancer
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453685/
https://www.ncbi.nlm.nih.gov/pubmed/37623040
http://dx.doi.org/10.3390/curroncol30080559
work_keys_str_mv AT pretibeatricetb realworldanalysisofdurvalumabafterchemoradiationinstageiiinonsmallcelllungcancer
AT sanatanimichaels realworldanalysisofdurvalumabafterchemoradiationinstageiiinonsmallcelllungcancer
AT breadnerdaniel realworldanalysisofdurvalumabafterchemoradiationinstageiiinonsmallcelllungcancer
AT lakkunarajahsuganija realworldanalysisofdurvalumabafterchemoradiationinstageiiinonsmallcelllungcancer
AT scottcarolyn realworldanalysisofdurvalumabafterchemoradiationinstageiiinonsmallcelllungcancer
AT esmondewhitecaroline realworldanalysisofdurvalumabafterchemoradiationinstageiiinonsmallcelllungcancer
AT mcarthureric realworldanalysisofdurvalumabafterchemoradiationinstageiiinonsmallcelllungcancer
AT rodriguesgeorge realworldanalysisofdurvalumabafterchemoradiationinstageiiinonsmallcelllungcancer
AT chaudharymitali realworldanalysisofdurvalumabafterchemoradiationinstageiiinonsmallcelllungcancer
AT mutsaersadam realworldanalysisofdurvalumabafterchemoradiationinstageiiinonsmallcelllungcancer
AT sachdevarobin realworldanalysisofdurvalumabafterchemoradiationinstageiiinonsmallcelllungcancer
AT vincentmarkd realworldanalysisofdurvalumabafterchemoradiationinstageiiinonsmallcelllungcancer